| Recruiting | 2 | 90 | Canada | INT230-6, Cisplatin, Vinblastine, 2-hydroxybenzoylaminooctanoate (SAHO), Saline injection | Ottawa Hospital Research Institute, Intensity Therapeutics, Inc., Ontario Institute for Cancer Research | Breast Cancer | 03/22 | 03/23 | | |
| Completed | 1/2 | 110 | Canada, US | INT230-6, anti-PD-1 antibody, pembrolizumab, Keytruda, MK-3475, anti-CTLA-4 antibody, ipilimumab, Yervoy, BMS-734016 | Intensity Therapeutics, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb | Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma | 02/23 | 02/23 | | |
